



Rabbit Anti-Durvalumab polyclonal antibody (CABT-ZB265)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB265 is produced from sera of a rabbit immunized with Durvalumab.
Specificity	The product is specific for Durvalumab.
Target	Durvalumab
Immunogen	Durvalumab
Isotype	IgG
Source/Host	Rabbit
Purification	Affinity purification
Conjugate	Unconjugated
Applications	Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.01-0.1 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg
Buffer	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Preservative	0.02% sodium azide

Storage The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.

Ship Wet ice

BACKGROUND

Introduction Durvalumab (Imfinzi) is a human IgG1κ monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.

Keywords Rabbit polyclonal antibody to Imfinzi; Durvalumab; Imfinz; MEDI-4736

GENE INFORMATION

Synonyms Rabbit polyclonal antibody to Imfinzi; Durvalumab; Imfinz; MEDI-4736
